Urinary tract infection (UTI) is a microbial infection caused by bacteria, fungi, and in rare cases by viruses. The urinary tract comprises kidneys, ureters, bladder, and urethra. Most UTIs only involve the urethra and bladder in the lower tract. Urinary tract infection is a life-threatening disease due to transmission of the infection from kidney to blood which causes urosepsis, with symptoms such as dangerously low blood pressure, shock, and death. The type of antibiotics prescribed depends on what part of the tract is to be treated. However, developments in route of administration and different concentration of drugs enable prevention of the disease or infection to spread at the cellular and molecular level.

High prevalence of diseases such as diabetes and kidney stone, increase in incidence of urinary tract infection among adults, surge in patient awareness, rise in research and development initiatives, advent of high-throughput screening (HTS) for drug discovery, and FDA approvals for drugs are the major factors driving the global urinary tract infection market. According to the Nature Reviews Microbiology (2016), urinary tract infections are the most common bacterial infections, affecting 150 million people each year globally. Currently, the societal cost of these infections, including health care costs and time missed from work, is approximately US$ 3.5 Bn per year in the U.S. alone. The rate of infection burden can be reduced through early detection of urinary tract infection and management of patients who develop kidney stone. Increase in the number of patients with chronic diseases, rise in the geriatric population, surge in awareness about minimally invasive techniques, and FDA approval of drugs are projected to fuel the growth of the global urinary tract infection market. However, factors such as increasing incidence of cancer and cost of diagnosis are expected to hamper the growth of the global urinary tract infection market.

The global urinary tract infection market can be segmented based on drug, route of administration, distribution channel, and region. In terms of drug, the urinary tract infection market can be classified into quinolones, penicillin & combinations, cephalosporin, azoles & amphotericin B, sulphonamides, aminoglycoside-antibodies, nitrofurans, and tetracycline. Based on route of administration, the global urinary tract infection market can be categorized into intravenous, oral, and others. Oral is a fast growing segment owing to increase in rate of infection of the upper tract UTI among patients. In terms of distribution channel, the urinary tract infection market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies.                                                                                                          

In terms of region, the global urinary tract infection market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017 due to increase in funding for the development of research and health care infrastructure. Increase in incidence of urinary tract infections and early diagnosis and treatment of diseases drive the medical biotechnology segment, which in turn is projected to boost the growth of the urinary tract infection market in North America. Europe is the second largest market for urinary tract infection treatment, due to favorable government policies toward development of health care infrastructure and pharmaceutical companies. The urinary tract infection market in Asia Pacific is expected to expand at a high CAGR during the forecast period due to rise in population with urinary tract infection, surge in awareness among patients, and increase in per capita expenditure. Additionally, economic growth in India and China supports the health care infrastructure as well as expansion of pharmaceutical companies and biotech labs.

Major players operating in the global urinary tract infection market are Pfizer, Inc., AstraZeneca plc, Novartis AG., Johnson & Johnson, F. Hoffmann La-Roche Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Cipla Ltd., and Rempex Pharmaceuticals, among others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • The Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates are included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

.